On the stock market since 2019, it operates in the world of health and science. It has 154 employees. Now — the numbers.
The company is still in the product-building phase: its spending runs above its sales. That only changes once the product starts selling at scale.
An average decline of 68% a year over the last 4 years — the most striking risk in this picture. Red columns mark years that ended in a loss.
Executives buying with their own money is usually read as confidence in the company’s future.
An investor who bought at the very peak is down 61% today. The business is the same; what changed most is the price — and the expectations — the market pins on it.
Sales run at $72K a year. A small number, but proof the product has real buyers.
There is $504K in the vault; even if every debt were paid off, $504K would remain.
Over the last 12 months, company executives reported 12 buys and 10 sells. Management buying with its own money is usually read as a good sign.
A loss of $0 against $72K in annual sales. And on top of that, sales fell from the year before.
Since the drop from its peak, buyer appetite hasn’t come back.
On our five-subject report card, IMAC sits behind the class. A low grade doesn’t mean “doomed” — it means “big claim, small proof.”
The takeaway: IMAC is a high-risk stock — not yet profitable, and its future rides on its product catching on.